MGNX / MacroGenics: Non-Dilutive Funding Propels Drug Candidates (Rating Upgrade)

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered more_horizontal

MacroGenics saw a big jump in net income. It receives royalties from Sanofi for breast cancer drug Tzield. more_horizontal

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jim Karrels - VP and CFO Scott Koenig more_horizontal

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing an more_horizontal

MacroGenics demonstrates promise with its drug lorigerlimab for mCRPC treatment, despite a recent 18% stock price drop. Q1 2023 showed financial growt more_horizontal

MacroGenics (MGNX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $1.07. This compares to loss of $1.08 per more_horizontal

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializ more_horizontal

Two analysts raised their price targets on the cancer-focused biotech. They are the latest prognosticators to adjust their takes on the company follow more_horizontal